A	O
16	O
Yin	B:C0017337
Yang	I:C0017337
gene	O
expression	I:C0017262
ratio	O
signature	O
for	O
ER	O
+	I:C2938924
/	O
node-	O
breast	I:C3160889
cancer	I:C3160889
.	O

A	O
16	O
Yin	O
Yang	I:C0017337
gene	B:C0017262
expression	I:C0017262
ratio	O
signature	O
for	O
ER	O
+	I:C2938924
/	O
node-	O
breast	I:C3160889
cancer	I:C3160889
.	O

A	O
16	O
Yin	O
Yang	I:C0017337
gene	O
expression	I:C0017262
ratio	O
signature	O
for	O
ER	B:C2938924
+	I:C2938924
/	O
node-	O
breast	I:C3160889
cancer	I:C3160889
.	O

A	O
16	O
Yin	O
Yang	I:C0017337
gene	O
expression	I:C0017262
ratio	O
signature	O
for	O
ER	O
+	I:C2938924
/	O
node-	B:C3160889
breast	I:C3160889
cancer	I:C3160889
.	O

Breast	B:C0006142
cancer	I:C0006142
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	O
death	O
in	O
women	O
.	O

Breast	O
cancer	I:C0006142
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	B:C0006826
death	O
in	O
women	O
.	O

Breast	O
cancer	I:C0006142
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	O
death	B:C0011065
in	O
women	O
.	O

Breast	O
cancer	I:C0006142
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	O
death	O
in	O
women	B:C0043210
.	O

It	O
is	O
a	O
complex	O
and	O
heterogeneous	O
disease	B:C0012634
with	O
different	O
clinical	O
outcomes	O
.	O

Stratifying	O
patients	O
into	O
subgroups	B:C1515021
with	O
different	O
outcomes	O
could	O
help	O
guide	O
clinical	O
decision	I:C4042877
making	I:C4042877
.	O

Stratifying	O
patients	O
into	O
subgroups	O
with	O
different	O
outcomes	O
could	O
help	O
guide	O
clinical	B:C4042877
decision	I:C4042877
making	I:C4042877
.	O

In	O
this	O
study	B:C0008972
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	O
,	O
Yin	O
and	I:C0017337
Yang	I:C0017337
,	O
to	O
develop	O
a	O
prognostic	O
expression	O
ratio	O
signature	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	B:C0017337
,	O
Yin	O
and	I:C0017337
Yang	I:C0017337
,	O
to	O
develop	O
a	O
prognostic	O
expression	O
ratio	O
signature	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	O
,	O
Yin	B:C0017337
and	I:C0017337
Yang	I:C0017337
,	O
to	O
develop	O
a	O
prognostic	O
expression	O
ratio	O
signature	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	O
,	O
Yin	O
and	I:C0017337
Yang	I:C0017337
,	O
to	O
develop	O
a	O
prognostic	B:C1511294
expression	O
ratio	O
signature	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	O
,	O
Yin	O
and	I:C0017337
Yang	I:C0017337
,	O
to	O
develop	O
a	O
prognostic	O
expression	B:C0017262
ratio	O
signature	O
.	O

Using	O
the	O
METABRIC	B:C0242356
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	B:C0086027
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	B:C0006142
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	B:C1515119
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	B:C0205103
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	B:C0332293
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	B:C0279025
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	B:C0205103
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	B:C0332293
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	B:C3665472
in	O
addition	O
to	O
the	O
hormonal	O
therapy	I:C0279025
.	O

Using	O
the	O
METABRIC	O
cohort	O
we	O
identified	O
a	O
16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	O
cancer	I:C0006142
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	O
therapy	I:C1515119
,	O
intermediate	O
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	O
with	I:C0332293
hormonal	O
therapy	I:C0279025
only	O
,	O
and	O
intermediate	O
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	O
by	O
chemotherapy	O
in	O
addition	O
to	O
the	O
hormonal	B:C0279025
therapy	I:C0279025
.	O

The	O
16	O
-	O
gene	O
signature	O
for	O
four	O
risk	O
level	O
stratifications	B:C0008902
of	O
breast	O
cancer	I:C0006142
patients	O
has	O
been	O
validated	O
using	O
14	O
independent	O
datasets	O
.	O

The	O
16	O
-	O
gene	O
signature	O
for	O
four	O
risk	O
level	O
stratifications	O
of	O
breast	B:C0006142
cancer	I:C0006142
patients	O
has	O
been	O
validated	O
using	O
14	O
independent	O
datasets	O
.	O

The	O
16	O
-	O
gene	O
signature	O
for	O
four	O
risk	O
level	O
stratifications	O
of	O
breast	O
cancer	I:C0006142
patients	O
has	O
been	O
validated	B:C1519941
using	O
14	O
independent	O
datasets	O
.	O

The	O
16	O
-	O
gene	O
signature	O
for	O
four	O
risk	O
level	O
stratifications	O
of	O
breast	O
cancer	I:C0006142
patients	O
has	O
been	O
validated	O
using	O
14	O
independent	O
datasets	B:C0150098
.	O

Notably	O
,	O
the	O
low	O
-	O
risk	O
group	B:C1257890
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	O
receptor	I:C2938924
-	I:C2938924
positive	I:C2938924
and	O
node	O
negative	I:C3160889
(	O
ER+	O
/	O
node	O
-)	I:C3160889
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	O
therapy	I:C0677850
had	O
100	O
%	O
15	O
-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O

Notably	O
,	O
the	O
low	O
-	O
risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	B:C2938924
receptor	I:C2938924
-	I:C2938924
positive	I:C2938924
and	O
node	O
negative	I:C3160889
(	O
ER+	O
/	O
node	O
-)	I:C3160889
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	O
therapy	I:C0677850
had	O
100	O
%	O
15	O
-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O

Notably	O
,	O
the	O
low	O
-	O
risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	O
receptor	I:C2938924
-	I:C2938924
positive	I:C2938924
and	O
node	B:C3160889
negative	I:C3160889
(	O
ER+	O
/	O
node	O
-)	I:C3160889
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	O
therapy	I:C0677850
had	O
100	O
%	O
15	O
-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O

Notably	O
,	O
the	O
low	O
-	O
risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	O
receptor	I:C2938924
-	I:C2938924
positive	I:C2938924
and	O
node	O
negative	I:C3160889
(	O
ER+	B:C2938924
/	O
node	O
-)	I:C3160889
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	O
therapy	I:C0677850
had	O
100	O
%	O
15	O
-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O

Notably	O
,	O
the	O
low	O
-	O
risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	O
receptor	I:C2938924
-	I:C2938924
positive	I:C2938924
and	O
node	O
negative	I:C3160889
(	O
ER+	O
/	O
node	B:C3160889
-)	I:C3160889
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	O
therapy	I:C0677850
had	O
100	O
%	O
15	O
-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O

Notably	O
,	O
the	O
low	O
-	O
risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	O
receptor	I:C2938924
-	I:C2938924
positive	I:C2938924
and	O
node	O
negative	I:C3160889
(	O
ER+	O
/	O
node	O
-)	I:C3160889
patients	O
from	O
three	O
different	O
datasets	B:C0150098
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	O
therapy	I:C0677850
had	O
100	O
%	O
15	O
-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O

Notably	O
,	O
the	O
low	O
-	O
risk	O
group	O
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	O
receptor	I:C2938924
-	I:C2938924
positive	I:C2938924
and	O
node	O
negative	I:C3160889
(	O
ER+	O
/	O
node	O
-)	I:C3160889
patients	O
from	O
three	O
different	O
datasets	O
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	B:C0677850
therapy	I:C0677850
had	O
100	O
%	O
15	O
-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O

The	O
Concordance	B:C0918012
Index	I:C0918012
of	O
YMR	O
for	O
ER	O
+	I:C2938924
/	O
node	O
negative	I:C3160889
patients	O
is	O
close	O
to	O
the	O
commercially	O
available	O
signatures	O
.	O

The	O
Concordance	O
Index	I:C0918012
of	O
YMR	B:C2698560
for	O
ER	O
+	I:C2938924
/	O
node	O
negative	I:C3160889
patients	O
is	O
close	O
to	O
the	O
commercially	O
available	O
signatures	O
.	O

The	O
Concordance	O
Index	I:C0918012
of	O
YMR	O
for	O
ER	B:C2938924
+	I:C2938924
/	O
node	O
negative	I:C3160889
patients	O
is	O
close	O
to	O
the	O
commercially	O
available	O
signatures	O
.	O

The	O
Concordance	O
Index	I:C0918012
of	O
YMR	O
for	O
ER	O
+	I:C2938924
/	O
node	B:C3160889
negative	I:C3160889
patients	O
is	O
close	O
to	O
the	O
commercially	O
available	O
signatures	O
.	O

The	O
Concordance	O
Index	I:C0918012
of	O
YMR	O
for	O
ER	O
+	I:C2938924
/	O
node	O
negative	I:C3160889
patients	O
is	O
close	O
to	O
the	O
commercially	B:C0680536
available	O
signatures	O
.	O

However	O
,	O
YMR	B:C2698560
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
subgroup	O
than	O
OncotypeDx	O
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
-	O
7	O
)	O
,	O
MammaPrint	O
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
-	O
7	O
)	O
,	O
rorS	O
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
-	O
6	O
)	O
,	O
and	O
NPI	O
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
-	O
6	O
)	O
.	O

However	O
,	O
YMR	O
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	B:C2938924
+	I:C2938924
/	O
node	O
-	I:C3160889
subgroup	O
than	O
OncotypeDx	O
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
-	O
7	O
)	O
,	O
MammaPrint	O
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
-	O
7	O
)	O
,	O
rorS	O
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
-	O
6	O
)	O
,	O
and	O
NPI	O
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
-	O
6	O
)	O
.	O

However	O
,	O
YMR	O
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	O
+	I:C2938924
/	O
node	B:C3160889
-	I:C3160889
subgroup	O
than	O
OncotypeDx	O
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
-	O
7	O
)	O
,	O
MammaPrint	O
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
-	O
7	O
)	O
,	O
rorS	O
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
-	O
6	O
)	O
,	O
and	O
NPI	O
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
-	O
6	O
)	O
.	O

However	O
,	O
YMR	O
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
subgroup	B:C1515021
than	O
OncotypeDx	O
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
-	O
7	O
)	O
,	O
MammaPrint	O
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
-	O
7	O
)	O
,	O
rorS	O
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
-	O
6	O
)	O
,	O
and	O
NPI	O
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
-	O
6	O
)	O
.	O

However	O
,	O
YMR	O
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
subgroup	O
than	O
OncotypeDx	B:C2698560
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
-	O
7	O
)	O
,	O
MammaPrint	O
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
-	O
7	O
)	O
,	O
rorS	O
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
-	O
6	O
)	O
,	O
and	O
NPI	O
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
-	O
6	O
)	O
.	O

However	O
,	O
YMR	O
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
subgroup	O
than	O
OncotypeDx	O
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
-	O
7	O
)	O
,	O
MammaPrint	B:C2827401
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
-	O
7	O
)	O
,	O
rorS	O
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
-	O
6	O
)	O
,	O
and	O
NPI	O
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
-	O
6	O
)	O
.	O

However	O
,	O
YMR	O
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
subgroup	O
than	O
OncotypeDx	O
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
-	O
7	O
)	O
,	O
MammaPrint	O
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
-	O
7	O
)	O
,	O
rorS	B:C2698560
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
-	O
6	O
)	O
,	O
and	O
NPI	O
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
-	O
6	O
)	O
.	O

However	O
,	O
YMR	O
showed	O
more	O
significance	O
(	O
HR	O
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
subgroup	O
than	O
OncotypeDx	O
(	O
HR	O
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
-	O
7	O
)	O
,	O
MammaPrint	O
(	O
HR	O
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
-	O
7	O
)	O
,	O
rorS	O
(	O
HR	O
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
-	O
6	O
)	O
,	O
and	O
NPI	B:C2698560
(	O
HR	O
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
-	O
6	O
)	O
.	O

YMR	B:C2698560
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	O
of	O
low	O
-	O
risk	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	O
therapy	I:C0279025
(	O
adjuvant	O
hormonal	I:C0279025
therapy	I:C0279025
)	O
.	O

YMR	O
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	B:C0037589
to	O
select	O
a	O
subgroup	O
of	O
low	O
-	O
risk	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	O
therapy	I:C0279025
(	O
adjuvant	O
hormonal	I:C0279025
therapy	I:C0279025
)	O
.	O

YMR	O
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	B:C1515021
of	O
low	O
-	O
risk	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	O
therapy	I:C0279025
(	O
adjuvant	O
hormonal	I:C0279025
therapy	I:C0279025
)	O
.	O

YMR	O
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	O
of	O
low	O
-	O
risk	O
ER	B:C2938924
+	I:C2938924
/	O
node	O
-	I:C3160889
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	O
therapy	I:C0279025
(	O
adjuvant	O
hormonal	I:C0279025
therapy	I:C0279025
)	O
.	O

YMR	O
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	O
of	O
low	O
-	O
risk	O
ER	O
+	I:C2938924
/	O
node	B:C3160889
-	I:C3160889
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	O
therapy	I:C0279025
(	O
adjuvant	O
hormonal	I:C0279025
therapy	I:C0279025
)	O
.	O

YMR	O
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	O
of	O
low	O
-	O
risk	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	B:C0279025
therapy	I:C0279025
(	O
adjuvant	O
hormonal	I:C0279025
therapy	I:C0279025
)	O
.	O

YMR	O
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	O
to	O
select	O
a	O
subgroup	O
of	O
low	O
-	O
risk	O
ER	O
+	I:C2938924
/	O
node	O
-	I:C3160889
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	O
therapy	I:C0279025
(	O
adjuvant	B:C0279025
hormonal	I:C0279025
therapy	I:C0279025
)	O
.	O

